Litigation Details for Eli Lilly and Company v. Cipla USA, Inc. (E.D. Va. 2016)

Eli Lilly and Company v. Cipla USA, Inc. (E.D. Va. 2016)

Docket		Date Filed	2016-09-22
Court	District Court, E.D. Virginia	Date Terminated	2017-07-11
Cause	35:271 Patent Infringement	Assigned To	Anthony John Trenga
Jury Demand	None	Referred To	Michael S. Nachmanoff
Patents	6,943,166
Link to Docket	External link to docket

Details for Eli Lilly and Company v. Cipla USA, Inc. (E.D. Va. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-09-22				External link to document
2016-09-22	4		determination of an action regarding patent and/or trademark(s) 6,943,166. (dest, ) (Entered: 09/23/2016) …2016 11 July 2017 1:16-cv-01208 830 Patent None District Court, E.D. Virginia	External link to document

Eli Lilly and Company v. Cipla USA, Inc. Litigation Analysis

Last updated: February 19, 2026

This document analyzes the patent litigation between Eli Lilly and Company and Cipla USA, Inc., concerning CGRP inhibitor patents. The litigation, filed in the U.S. District Court for the District of Delaware, focuses on allegations of induced infringement of several Eli Lilly patents by Cipla's proposed generic versions of erenumab-aooe (brand name Aimovig).

What are the Key Patents in Dispute?

The core of the litigation revolves around U.S. Patent Nos. 8,703,760; 9,441,063; and 9,617,269. These patents claim methods of treating migraine headaches by administering a calcitonin gene-related peptide (CGRP) inhibitor. Eli Lilly alleges that Cipla's proposed generic product, intended for the treatment of migraine, directly infringes these patents.

• U.S. Patent No. 8,703,760: This patent claims a method of treating a migraine condition. It specifies administering an antibody or antibody fragment that binds to CGRP.
• U.S. Patent No. 9,441,063: This patent claims a method for treating a migraine condition. It involves administering an antibody that binds to CGRP.
• U.S. Patent No. 9,617,269: This patent also claims a method of treating a migraine condition. It involves administering an antibody that binds to CGRP.

The patents were issued on April 21, 2015; December 13, 2016; and April 10, 2018, respectively.

What are the Allegations of Infringement?

Eli Lilly alleges that Cipla USA, Inc. has infringed and continues to infringe Eli Lilly's patents. The primary allegation is that Cipla's actions constitute induced infringement. This means Eli Lilly claims Cipla is actively encouraging or aiding others (specifically, prescribers and patients) to engage in activities that would directly infringe Eli Lilly's patents.

Eli Lilly's complaint states that Cipla has submitted an Abbreviated New Drug Application (ANDA) for a generic version of erenumab-aooe. Erenumab-aooe is a CGRP inhibitor used for the prevention of migraine. Eli Lilly argues that Cipla's proposed generic product is designed to perform the same function as erenumab-aooe and is intended for the same patented methods of treatment.

The allegations of induced infringement are based on Cipla's intent to market and sell a product that would be used to practice the claimed methods. Eli Lilly asserts that Cipla knows that the intended use of its generic erenumab-aooe product is to treat migraine headaches, a method protected by Eli Lilly's patents.

What is the Status of the Litigation?

The litigation, filed on December 16, 2016, is ongoing. The case is proceeding in the U.S. District Court for the District of Delaware, a common venue for pharmaceutical patent disputes due to its established patent law precedent and experienced judges.

The parties are engaged in the typical discovery phases of patent litigation. This includes the exchange of documents, written interrogatories, and depositions. Eli Lilly is seeking a preliminary and permanent injunction to prevent Cipla from launching its generic product. They also seek damages for any infringement that may have occurred.

What are the Potential Outcomes and Implications?

The outcome of this litigation has significant implications for both Eli Lilly and the generic pharmaceutical industry.

• For Eli Lilly: A favorable ruling would uphold the validity and enforceability of their CGRP inhibitor patents, protecting their market exclusivity for erenumab-aooe. This would allow them to continue to derive revenue from this important drug without direct generic competition for the duration of the patent term. A loss could open the door for generic competition sooner than anticipated, impacting Eli Lilly's revenue streams.
• For Cipla USA, Inc.: A successful defense would allow Cipla to launch its generic erenumab-aooe product, providing consumers with a potentially lower-cost alternative and establishing Cipla's presence in the CGRP inhibitor market. An unfavorable ruling would prevent or delay their market entry.
• For the Broader Market: The litigation contributes to the ongoing legal and scientific debate surrounding the patentability and enforceability of methods of treatment using biologics, particularly for complex diseases like migraine. The court's decision could set precedents for future patent challenges involving similar therapeutic classes.

The case could result in a settlement, a bench trial, or a jury trial. The duration of the litigation is difficult to predict and will depend on the complexity of the legal and scientific arguments, as well as the court's docket.

Key Takeaways

• Eli Lilly and Company is suing Cipla USA, Inc. for induced infringement of U.S. Patent Nos. 8,703,760; 9,441,063; and 9,617,269.
• The patents cover methods of treating migraine headaches using CGRP inhibitors.
• Cipla is alleged to have infringed these patents through its submission of an ANDA for a generic version of erenumab-aooe.
• The litigation is ongoing in the U.S. District Court for the District of Delaware.
• The outcome will impact market exclusivity for erenumab-aooe and the competitive landscape for CGRP inhibitors.

Frequently Asked Questions

What is CGRP and why is it important for migraine treatment?

Calcitonin gene-related peptide (CGRP) is a neuropeptide that plays a significant role in the pathophysiology of migraine headaches. It is involved in vasodilation and pain transmission. Inhibiting CGRP or its receptor has been shown to be an effective strategy for both acute treatment and prevention of migraine attacks.

What is an Abbreviated New Drug Application (ANDA)?

An Abbreviated New Drug Application (ANDA) is submitted to the U.S. Food and Drug Administration (FDA) by companies seeking approval to market a generic version of an already approved brand-name drug. An ANDA must demonstrate that the generic drug is bioequivalent to the brand-name drug and contains the same active ingredient, dosage form, strength, and route of administration.

What is induced infringement in patent law?

Induced infringement occurs when a party actively encourages or aids another party to infringe a patent. This requires proof of direct infringement by the end-user and that the alleged inducer knew of the patent and intended to induce the infringement. In this context, Eli Lilly alleges that Cipla intended for prescribers and patients to use its generic drug in a manner that infringes Eli Lilly's method-of-treatment patents.

What is the significance of the chosen court (District of Delaware)?

The District of Delaware is a preferred venue for pharmaceutical patent litigation in the United States. It has a specialized section dedicated to patent cases with judges who have extensive experience in patent law. This can lead to more efficient and predictable proceedings compared to other districts.

What are the potential defenses Cipla USA, Inc. might raise?

Cipla could raise several defenses, including but not limited to:

• Non-infringement: Arguing that their product or the method of its use does not fall within the scope of Eli Lilly's patent claims.
• Patent invalidity: Challenging the validity of Eli Lilly's patents based on prior art, lack of novelty, obviousness, or insufficient written description.
• Lack of enablement: Contending that the patents do not adequately describe how to make and use the invention.
• Merchants of mere materials: Arguing that they are merely supplying a component and not actively inducing infringement, especially if the drug has multiple uses.

What is the typical timeline for patent litigation like this?

Pharmaceutical patent litigation, particularly involving ANDA challenges, can be lengthy. While some cases settle early, complex disputes often proceed through discovery, claim construction hearings (Markman hearings), potential summary judgment motions, and ultimately trial. A trial can occur 18-30 months after the initial filing, with appeals extending the process further. The outcome of the Hatch-Waxman Act's 30-month stay on FDA approval can also influence the timeline.

Cited Sources

[1] Complaint for Patent Infringement, Eli Lilly and Company v. Cipla USA, Inc., No. 1:16-cv-01208 (D. Del. Dec. 16, 2016).